Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Filter by:

Featured

Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

EHA 2023

Platzbecker, et. al.

Analysis of Patient Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Lower Risk MDS

Clinical Imetelstat: MDS Imetelstat

EHA 2023

Sekeres, et. al.

All

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

SOHO 2023

Sekeres, et. al

Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

SOHO 2023

Santini, et. al

Continuous Transfusion Independence with Imetelstat in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

SOHO 2023

Platzbecker, et. al.

Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

EHA 2023

Santini, et. al.

Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3

Clinical Imetelstat: MDS Imetelstat

EHA 2023

Platzbecker, et. al.

Analysis of Patient Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Lower Risk MDS

Clinical Imetelstat: MDS Imetelstat

EHA 2023

Sekeres, et. al.

Modulation of the immune landscape in lower-risk myelodysplastic syndromes with imetelstat-induced transfusion independency

Clinical Imetelstat: MDS Imetelstat

EHA 2023

Chapuis, et. al.

The telomerase inhibitor imetelstat differentially targets JAK2V617F- versus CALR-mutant Myeloproliferative Neoplasm cells and inhibits JAK-STAT signaling

Imetelstat Non-clinical Imetelstat: MF

EHA 2023

Chatain, et. al.

IMerge: Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Imetelstat in Patients with Lower-Risk MDS

Clinical Imetelstat: MDS Imetelstat

ASCO 2023

Zeidan, et al.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MF Imetelstat

ASH 2022

Mascarenhas, et al.

An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

Clinical Imetelstat: MF Imetelstat

ASH 2022

Bradley T, et al.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Clinical Imetelstat: MDS Imetelstat

ASH 2022

Platzbecker, et al.

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Imetelstat Non-clinical Imetelstat

ASH 2022

Bruedigam C, et al.

Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma

Imetelstat Non-clinical Imetelstat

Blood 2022

Aradhya A, et al.

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

Clinical Imetelstat: MF Imetelstat

Future Oncology 2022

Mascarenhas, et al.

Patients

We are on a mission to improve and extend lives

Discover more about our commitment to patients

Learn more